Press Release
Apr 11 2024
FORE Biotherapeutics presenting at Stifel 2024 Virtual Targeted Oncology Forum
Read more
FORE Biotherapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Press Release
May 10, 2024 11:17 AM EDT
PHILADELPHIA – May 10, 2024 – FORE Biotherapeutics today announced that the Company will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference. The presentation will take place on Wednesday, May 15, 2024 at 9:00-9:25 AM ET.
William Hinshaw, Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact your RBC Capital Markets salesperson or Argot Partners to schedule one-on-one meetings with the management team.
About FORE Biotherapeutics
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.
Investors and Media:
Argot Partners
